Acinetobacter baumannii pneumonia increases surfactant proteins SP-A, SP-B, and SP-D levels, while decreasing SP-C level in bronchoalveolar lavage in rats

Özarslan, Talat Oğulcan; Sırmatel, Fatma; Karabörk, Şeyda Özsoy; Düzcü, Selma Erdoğan; Astarci, Hesna Muzeyyen

doi:10.1016/j.micinf.2022.105064

Cited by 2 publications

(2 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…129 Experimental evidence suggests that phosphatidylcholine can serve as a nutrient source during pulmonary infections caused by pathogens like Pseudomonas aeruginosa and A. baumannii. 130 The degradation of phospholipids by these enzymes compromises the stability of host cell membranes and directly interferes with cell signaling, resulting in alterations in the host's immune response. 127 Another identified virulence factor is the CpaA enzyme, characterized as a metallo-endopeptidase with similarities to adamalysin, specifically targeting glycans.…”

Section: Phospholipasesmentioning

confidence: 99%

Treatment and Management of Acinetobacter Pneumonia: Lessons Learned from Recent World Event

Rangel,

De-Simone

2024

IDR

View full text Add to dashboard Cite

Acinetobacter pneumonia is a significant healthcare-associated infection that poses a considerable challenge to clinicians due to its multidrug-resistant nature. Recent world events, such as the COVID-19 pandemic, have highlighted the need for effective treatment and management strategies for Acinetobacter pneumonia. In this review, we discuss lessons learned from recent world events, particularly the COVID-19 pandemic, in the context of the treatment and management of Acinetobacter pneumonia. We performed an extensive literature review to uncover studies and information pertinent to the topic. The COVID-19 pandemic underscored the importance of infection control measures in healthcare settings, including proper hand hygiene, isolation protocols, and personal protective equipment use, to prevent the spread of multidrug-resistant pathogens like Acinetobacter . Additionally, the pandemic highlighted the crucial role of antimicrobial stewardship programs in optimizing antibiotic use and curbing the emergence of resistance. Advances in diagnostic techniques, such as rapid molecular testing, have also proven valuable in identifying Acinetobacter infections promptly. Furthermore, due to the limited availability of antibiotics for treating infections caused A. baumannii , alternative strategies are needed like the use of antimicrobial peptides, bacteriophages and their enzymes, nanoparticles, photodynamic and chelate therapy. Recent world events, particularly the COVID-19 pandemic, have provided valuable insights into the treatment and management of Acinetobacter pneumonia. These lessons emphasize the significance of infection control, antimicrobial stewardship, and early diagnostics in combating this challenging infection.

show abstract

Section: Phospholipasesmentioning

confidence: 99%

Treatment and Management of Acinetobacter Pneumonia: Lessons Learned from Recent World Event

Rangel,

De-Simone

2024

IDR

View full text Add to dashboard Cite

show abstract

“…In A. baumannii , have been identified two phospholipases C (A1S_0043 and A1S_2055) and three phospholipases D (PLD1, PLD2, PLD3), all with substrate specificity toward the eukaryotic membrane component phosphatidylcholine (PC; Flores-Díaz et al, 2016 ). PC is abundant in eukaryotic membranes representing 50% of all phospholipids and increasing up to 80% in the lung and tracheobronchial secretions ( Girod et al, 1992 ; Bernhard et al, 2001 ; Tomaras et al, 2003 ) Experimental evidence suggests that it may serve as a nutrient source during lung infections by pathogens like Pseudomonas aeruginosa and A. baumannii ( McConnell et al, 2013 ; Sun et al, 2014 ; Özarslan et al, 2023 ). Phospholipids’ degradation compromises the stability of host cell membranes, interfering with cellular signaling, thus resulting in changes in the host immune response ( Flores-Díaz et al, 2016 ).…”

Section: Virulence and Pathogenicitymentioning

confidence: 99%

Acinetobacter baumannii in the critically ill: complex infections get complicated

et al. 2023

View full text Add to dashboard Cite

Acinetobacter baumannii is increasingly associated with various epidemics, representing a serious concern due to the broad level of antimicrobial resistance and clinical manifestations. During the last decades, A. baumannii has emerged as a major pathogen in vulnerable and critically ill patients. Bacteremia, pneumonia, urinary tract, and skin and soft tissue infections are the most common presentations of A. baumannii, with attributable mortality rates approaching 35%. Carbapenems have been considered the first choice to treat A. baumannii infections. However, due to the widespread prevalence of carbapenem-resistant A. baumannii (CRAB), colistin represents the main therapeutic option, while the role of the new siderophore cephalosporin cefiderocol still needs to be ascertained. Furthermore, high clinical failure rates have been reported for colistin monotherapy when used to treat CRAB infections. Thus, the most effective antibiotic combination remains disputed. In addition to its ability to develop antibiotic resistance, A. baumannii is also known to form biofilm on medical devices, including central venous catheters or endotracheal tubes. Thus, the worrisome spread of biofilm-producing strains in multidrug-resistant populations of A. baumannii poses a significant treatment challenge. This review provides an updated account of antimicrobial resistance patterns and biofilm-mediated tolerance in A. baumannii infections with a special focus on fragile and critically ill patients.

show abstract

Acinetobacter baumannii pneumonia increases surfactant proteins SP-A, SP-B, and SP-D levels, while decreasing SP-C level in bronchoalveolar lavage in rats

Cited by 2 publications

References 37 publications

Treatment and Management of Acinetobacter Pneumonia: Lessons Learned from Recent World Event

Treatment and Management of Acinetobacter Pneumonia: Lessons Learned from Recent World Event

Acinetobacter baumannii in the critically ill: complex infections get complicated

Contact Info

Product

Resources

About